Given a new treatment standard of chemotherapy plus bevacizumab, where to position cediranib is not readily discernible. Potential future trial designs might use strategies to study chemotherapy plus bevacizumab with and without cediranib, or randomisation to cediranib maintenance therapy in patients who derive clinical benefit from chemotherapy plus bevacizumab (eg, stable disease). If active as a monotherapy, a maintenance strategy containing cediranib could have major toxicology implications given that the median duration of cediranib treatment in both groups in CIRCCa was 19 weeks and overlapped with chemotherapy. Clearly, the results of CIRCCa provide additional clinical evidence that VEGF-dependent tumour angiogenesis remains a valid target in cervical cancer and that the need to explore novel anti-angiogenesis combinations and sequencing is implicit.